Ads
related to: statins that don't affect memory development problems and brain- Trial Results
See Clinical Data
and Trial
- Co-Pay Program
Resources
to Support Your Patients
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- MOA
Mechanism of Action -
Watch A Video To Learn More
- Request Samples
Get patients started
with a 14-day sample
- Resources
More Information
For Your Practice
- Trial Results
wiserlifestyles.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Statins with shorter half-lives are more effective when taken in the evening, so their peak effect occurs when the body's natural cholesterol production is at its highest. A recent meta-analysis suggested that statins with longer half-lives, including atorvastatin, may also be more effective at lowering LDL cholesterol if taken in the evening. [40]
Media reporting on statins is often negative, and patient leaflets inform patients that rare but potentially serious muscle problems can occur during statin treatment. These create expectations of harm. Nocebo symptoms are real and bothersome and are a major barrier to treatment.
Serious side effects may include rhabdomyolysis, liver problems, and diabetes. [6] Use during pregnancy may harm the baby. [6] Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol. [6]
Statins appear to be effective at preventing cardiovascular disease and death in older adults, according to new research. Most clinical trials evaluating statins have not included people 75 and ...
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
The statins differ with respect to their ring structure and substituents. These differences in structure affect the pharmacological properties of the statins, such as: [6] Affinity for the active site of the HMGR; Rates of entry into hepatic and non-hepatic tissues; Availability in the systemic circulation for uptake into non-hepatic tissues